At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed brain tumor (except brainstem locations) that is unlikely to respond to existing therapy and for which no curative therapy exists
- ✓Evidence of persistent or recurrent brain tumor on MRI scan performed within two weeks prior to study entry
- ✓Tumor must be at least 5 mm in size
- ✓Age 18 years and over
- ✕Brain tumors located in the brainstem
- ✕No prior antineoplaston therapy
- ✕Hepatic failure
- ✕History of renal conditions that contraindicate high dosages of sodium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors.
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Refractory Brain Tumors. Completed, enrolled 40 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with persistent or recurrent brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with persistent or recurrent brain tumors.
Study Details
Timeline
Interventions
Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).